Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
First-in-human safety and pharmacokinetics of MK-7602, the antimalarial inhibitor of plasmepsins IX/X, in single- and multiple-ascending-dose studies.
Journal: Antimicrobial agents and chemotherapy
Published: January 14, 2026
MK-7602: a potent multi-stage dual-targeting antimalarial.
Journal: EBioMedicine
Published: June 23, 2025
Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Journal: ImmunoHorizons
Published: February 04, 2025
Evaluation of the inhibitory effects of itraconazole on letermovir.
Journal: British journal of clinical pharmacology
Published: October 06, 2022
Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Journal: Clinical pharmacology and therapeutics
Published: June 30, 2021
Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle.
Journal: Cell host & microbe
Published: October 25, 2019
An APC/C-Cdh1 Biosensor Reveals the Dynamics of Cdh1 Inactivation at the G1/S Transition.
Journal: PloS one
Published: April 10, 2016
An essential malaria protein defines the architecture of blood-stage and transmission-stage parasites.
Journal: Nature communications
Published: September 17, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026